Primary source: View
Label change required for the product previously known as Rivaroxaban Koanaa to its new designation, Svariya.
This labeling update is crucial for ensuring accurate information dissemination to healthcare professionals and patients about the medication, which affects its safe and effective use.
Update all internal and external communications, labels, and marketing materials to reflect the new product name, Svariya, instead of Rivaroxaban Koanaa.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Update all internal and external communications, labels, and marketing materials to reflect the new product name, Svariya, instead of Rivaroxaban Koanaa.
Svariya, an anticoagulant medication, has been authorized in the EU under its new name following studies confirming its bioequivalence to the reference medicine, Xarelto. The change in name requires updates to promotional and regulatory materials.
What changed: Label change required for the product previously known as Rivaroxaban Koanaa to its new designation, Svariya.
Why it matters: This labeling update is crucial for ensuring accurate information dissemination to healthcare professionals and patients about the medication, which affects its safe and effective use.
Practical implication: Update all internal and external communications, labels, and marketing materials to reflect the new product name, Svariya, instead of Rivaroxaban Koanaa.
Published from the regulator source ingestion pipeline after PV impact triage.
Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.
Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.
Healthcare providers and manufacturers must now comply with new reporting obligations for adverse reactions associated with the use of Imaavy and ensure adherence to increased compliance requirements for its administration.
Stakeholders are advised to submit comments on the draft guidance by 11/18/2026, using docket number FDA-2026-D-8561 to ensure FDA considers their feedback before finalizing the document.
